for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Arbutus Biopharma Corp

ABUS.OQ

Latest Trade

0.88USD

Change

-0.05(-4.94%)

Volume

52,710

Today's Range

0.82

 - 

0.92

52 Week Range

0.82

 - 

5.64

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Arbutus Biopharma Q2 Loss Per Share $0.46

Arbutus Biopharma Corp <ABUS.O>::ARBUTUS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.46.Q2 EARNINGS PER SHARE ESTIMATE $-0.37 -- REFINITIV IBES DATA.SAYS RECEIVED $20 MILLION IN GROSS PROCEEDS FROM SALE OF A PORTION OF ONPATTRO ROYALTY ENTITLEMENT.CO BELIEVES ITS CASH AND INVESTMENTS BALANCE IS SUFFICIENT TO FUND OPERATIONS INTO SECOND HALF OF 2020.ANTICIPATE MOVING INTO A COMBINATION PROOF-OF-CONCEPT PHASE 2 CLINICAL TRIAL IN SUBJECTS WITH CHRONIC HEPATITIS B IN H2 2020.

Veritas Reaches A Mutual Settlement With Arbutus Biopharma Corporation

July 23 (Reuters) - Veritas Pharma Inc <VRT.CD>::VERITAS REACHES A MUTUAL SETTLEMENT WITH ARBUTUS BIOPHARMA CORPORATION.VERITAS PHARMA INC - HAS ENTERED INTO A CONFIDENTIAL SETTLEMENT THAT WILL RESOLVE THE ARBUTUS BIOPHARMA LITIGATION COMPLETELY.VERITAS PHARMA - REACHED SETTLEMENT WITH ARBUTUS BIOPHARMA REGARDING LITIGATION COMMENCED BY ARBUTUS FOR CLAIMS RELATED TO A COMMERCIAL LEASE SPACE.

Arbutus Announces Preliminary Early-Stage Clinical Trial Results For AB-506

July 15 (Reuters) - Arbutus Biopharma Corp <ABUS.O>::ARBUTUS ANNOUNCES PRELIMINARY PHASE 1A/1B CLINICAL TRIAL RESULTS FOR AB-506, AN ORAL CAPSID INHIBITOR IN DEVELOPMENT FOR PEOPLE WITH CHRONIC HEPATITIS B.ARBUTUS BIOPHARMA CORP - PHASE 1A/1B CLINICAL TRIAL TO CONTINUE WITH ENROLLMENT OF FURTHER COHORTS.ARBUTUS BIOPHARMA CORP - NO SERIOUS ADVERSE EVENTS OR CLINICALLY SIGNIFICANT SAFETY FINDINGS WERE OBSERVED IN HEALTHY SUBJECTS FOR AB-506.ARBUTUS BIOPHARMA CORP - NO SERIOUS ADVERSE EVENTS WERE OBSERVED IN CHRONIC HEPATITIS B SUBJECTS.

Arbutus Sells Part Of Its Onpattro Royalty Interest To Omers

July 2 (Reuters) - Arbutus Biopharma Corp <ABUS.O>::PRESS RELEASE - ARBUTUS SELLS PART OF ITS ONPATTRO™ (PATISIRAN) ROYALTY INTEREST TO OMERS.ARBUTUS BIOPHARMA CORP - ARBUTUS TO RECEIVE $20 MILLION IN GROSS PROCEEDS BEFORE ADVISORY FEES WHILE RETAINING SIGNIFICANT DOWNSTREAM ECONOMICS.ARBUTUS BIOPHARMA CORP - RUNWAY EXTENDED WITH NON-DILUTIVE CAPITAL.ARBUTUS BIOPHARMA CORP - ARBUTUS IS ENTITLED TO TIERED ROYALTY PAYMENTS ON NET SALES OF ONPATTRO RANGING FROM 1.00% - 2.33% AFTER OFFSETS.ARBUTUS BIOPHARMA CORP - ROYALTY INTEREST HAS BEEN SOLD TO OMERS, EFFECTIVE AS OF JANUARY 1, 2019, FOR $20 MILLION.

Arbutus Appoints William Collier As Next President & CEO

June 17 (Reuters) - Arbutus Biopharma Corp <ABUS.O>::ARBUTUS APPOINTS WILLIAM COLLIER AS NEXT PRESIDENT & CEO AND ANNOUNCES RETIREMENT OF CURRENT PRESIDENT & CEO, MARK J. MURRAY PH.D..ARBUTUS BIOPHARMA CORP - COLLIER HAS ALSO BEEN APPOINTED AS A MEMBER OF BOARD OF DIRECTORS OF ARBUTUS.ARBUTUS BIOPHARMA CORP - MURRAY WILL CONTINUE TO SERVE AS PRESIDENT AND CHIEF EXECUTIVE OFFICER UNTIL RETIREMENT ON JUNE 23RD.

Arbutus Q1 Loss Per Share $0.47

May 6 (Reuters) - Arbutus Biopharma Corp <ABUS.O>::ARBUTUS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.47.Q1 EARNINGS PER SHARE ESTIMATE $-0.32 -- REFINITIV IBES DATA.HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALING $110.6 MILLION AS OF MARCH 31, 2019.BELIEVE CASH AND INVESTMENTS BALANCE IS SUFFICIENT TO FUND OPERATIONS INTO 2020.

Arbutus Biopharma Corp Says On March 13, Koert Vandenenden, Announced Intention To Resign As Chief Accounting Officer - SEC Filing

March 15 (Reuters) - Arbutus Biopharma Corp <ABUS.O>::ARBUTUS BIOPHARMA CORP SAYS ON MARCH 13, KOERT VANDENENDEN, ANNOUNCED INTENTION TO RESIGN AS CHIEF ACCOUNTING OFFICER - SEC FILING.ARBUTUS BIOPHARMA CORP SAYS DAVID HASTINGS, COMPANY’S CFO, HAS BEEN APPOINTED AS COMPANY’S PRINCIPAL ACCOUNTING OFFICER.

Arbutus Biopharma Corp - Entered into an open market sale agreement with Jefferies LLC - SEC Filing

Dec 20 (Reuters) - Arbutus Biopharma Corp <ABUS.O>::ARBUTUS BIOPHARMA CORP - ENTERED INTO AN OPEN MARKET SALE AGREEMENT WITH JEFFERIES LLC - SEC FILING.ARBUTUS BIOPHARMA CORP - MAY ISSUE AND SELL ITS COMMON SHARES FROM TIME TO TIME FOR AN AGGREGATE SALES PRICE OF UP TO $50 MILLION THROUGH JEFFERIES.

Arbutus Reports Q3 Loss Per Share $0.49

Nov 7 (Reuters) - Arbutus Biopharma Corp <ABUS.O>::ARBUTUS REPORTS 2018 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.49.Q3 REVENUE $1.6 MILLION VERSUS $6.9 MILLION.Q3 REVENUE VIEW $211,000 -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.41 -- THOMSON REUTERS I/B/E/S.

Arbutus' LNP Licensee Alnylam Announces FDA Approval Of Onpattro

Aug 13 (Reuters) - Arbutus Biopharma Corp <ABUS.O>::ARBUTUS’ LNP LICENSEE ALNYLAM ANNOUNCES FDA APPROVAL OF ONPATTRO™ (PATISIRAN), FOR THE TREATMENT OF ATTR AMYLOIDOSIS.ARBUTUS BIOPHARMA CORP - ONPATTRO APPROVAL TRIGGERS ROYALTY TO ARBUTUS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up